Establishment Labs to Announce Second Quarter 2021 Financial Results on July 29
Establishment Labs Holdings (NASDAQ: ESTA) will release its financial results for Q2 2021 on July 29, 2021, prior to market open. A conference call is scheduled for 8:30 am ET the same day to discuss these results. The company specializes in women's health, particularly in breast aesthetics, and offers Motiva Implants®, which are available in over 80 countries. Established in 2018, they received FDA approval for a clinical trial in the U.S. for these implants.
- None.
- None.
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, plans to announce its financial results for the quarter ended June 30, 2021, before the market opens on Thursday, July 29, 2021, and will host a conference call at 8:30 am ET that day to discuss those results.
To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or (201) 689-8037 (International) and use conference ID number 13721659. The call will also be available via live or archived webcast on the “Investor Relations” section of the Establishment Labs website at www.establishmentlabs.com.
About Establishment Labs
Establishment Labs Holdings Inc. is a global medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, by designing, developing, manufacturing and marketing an innovative portfolio of silicone gel-filled breast implants, branded as Motiva Implants®, the centerpiece of the MotivaImagine® platform. Motiva Implants® are produced at our two manufacturing sites that are compliant with ISO13485:2016, FDA 21 CFR 820 under the MDSAP program, and are currently commercially available in more than 80 countries through exclusive distributors or the Company’s direct salesforce. In March 2018, Establishment Labs received approval for an investigational device exemption (IDE) from the FDA and initiated the Motiva Implant® clinical trial in the United States in April 2018. In addition to Motiva Implants®, Establishment Labs’ product and technologies portfolio includes the Divina® 3D Simulation System and other products and services. Please visit our website for additional information at www.establishmentlabs.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210716005054/en/
FAQ
When will Establishment Labs announce its financial results for Q2 2021?
What time is the conference call for Establishment Labs' Q2 2021 results?
How can I participate in the Establishment Labs conference call?
What products does Establishment Labs offer?
